2010年全球上市信息.xls

Sheet3 Sheet2 Sheet1 becaplermin + ?-tricalcium phosphate, BioMimetic-1 becaplermin + ?-TCP, BioMimeti becaplermin + ?-TCP, Luitpold becaplermin + ?-TCP, ZymoGenet becaplermin + ?-tricalcium pho becaplermin + ?-tricalcium pho GEM 21S GEM-21S Gemesis growth-factor enhanced matrix, rhPDGF-BB + ?-TCP, BioMimetic rhPDGF-BB + ?-TCP, Luitpold rhPDGF-BB + ?-TCP, ZymoGenetic rhPDGF-BB + ?-tricalcium phosp rhPDGF-BB + ?-tricalcium phosp rhPDGF-BB + ?-tricalcium phosp rhPDGF-BB, BioMimetic rhPDGF-BB, Luitpold rhPDGF-BB, ZymoGenetics BioMimetic Bristol-Myers Squibb Daiichi Sankyo Recombinant growth factor Platelet-derived growth factor beta receptor agonist Regeneration, bone Osteonecrosis Launched No Development Reported Orphan Drug Status Granted First Launches Additional Registrations Orphan Drug Status Granted New Indication First Registrations No Development Reported New Licensees Registration Submissions Change in Status New Licensees Change in Status New Product in Pharmaprojects The US; Osteochondritis dissecans Canada and the US Canada The US; Osteonecrosis Osteonecrosis The US - Luitpold Pharmaceuticals (Sankyo); Worldwide The EU Phase II Clinical Trial ZymoGenetics; Worldwide Phase I Clinical Trial - 2010/08/12 2010/03/15 2007/03/28 2007/03/28 2007/03/28 2005/11/02 2005/09/29 2004/01/08 2004/01/08 2002/09/04 2002/05/30 2002/05/30 2001/10/16 aztreonam lysine, Gilead AI aztreonam (inhaled) aztreonam, inhaled, Gilead Cayston Corus 1020 Gilead Sciences PARI Pharma Formulation, inhalable, topical Cell wall synthesis inhibitor Infection, respiratory tract, unspecified Bronchiectasis Launched Phase II Clinical Trial 104184-69-2 78110-38-0 Additional Launches First Launches Additional Registrations Additional Registrations First Registrations Additional Registrations Registration Submissions Registration Submissions Orphan Drug Status Granted Orphan Drug Status Granted Change in Status Change in Status Change in Status New Chemical Structure Orphan Drug Status Granted New P